当前位置：
X-MOL 学术
›
Eur. J. Pain
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
European Journal of Pain ( IF 3.5 ) Pub Date : 2021-03-16 , DOI: 10.1002/ejp.1764 Francis Berenbaum 1 , Richard Langford 2 , Serge Perrot 3 , Kenji Miki 4 , Francisco J Blanco 5 , Takaharu Yamabe 6 , Naoki Isogawa 7 , Rod Junor 8 , William Carey 8 , Lars Viktrup 9 , Christine R West 6 , Mark T Brown 6 , Kenneth M Verburg 6
European Journal of Pain ( IF 3.5 ) Pub Date : 2021-03-16 , DOI: 10.1002/ejp.1764 Francis Berenbaum 1 , Richard Langford 2 , Serge Perrot 3 , Kenji Miki 4 , Francisco J Blanco 5 , Takaharu Yamabe 6 , Naoki Isogawa 7 , Rod Junor 8 , William Carey 8 , Lars Viktrup 9 , Christine R West 6 , Mark T Brown 6 , Kenneth M Verburg 6
Affiliation
To evaluate if early improvements in pain and function with subcutaneous tanezumab are meaningful and sustained over 24 weeks.
中文翻译：
皮下注射 tanezumab 治疗骨关节炎：疼痛和功能的早期改善是否有意义和持续？
评估皮下注射 tanezumab 对疼痛和功能的早期改善是否有意义并持续超过 24 周。
更新日期：2021-03-16
中文翻译：
皮下注射 tanezumab 治疗骨关节炎：疼痛和功能的早期改善是否有意义和持续？
评估皮下注射 tanezumab 对疼痛和功能的早期改善是否有意义并持续超过 24 周。
京公网安备 11010802027423号